Shots:
- The approval is based on P-III CheckMate -743 study assessing Opdivo + Yervoy vs SOC Pt. based CT in patients with previously untreated unresectable malignant pleural mesothelioma
- The combination regimen has demonstrated significant extension of OS vs CT. The safety profile of combination treatment was consistent with those previously reported in the studies for the combination treatment
- Opdivo is a PD-1 immune checkpoint inhibitor, designed to harness the body’s immune system to help restore anti-tumor immune response. Yervoy is a recombinant, mAb and binds to the CTLA-4
Click here to read full press release/ article | Ref: Ono Pharma | Image: Ono Pharmaceutical
The post ONO and BMS’ Opdivo + Yervoy Receive Approval for 1L Treatment for Unresectable Advanced or Recurrent Malignant Pleural Mesothelioma first appeared on PharmaShots.
